Technical Analysis for IMM - Immupharma Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| See historical IMM trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 2.80% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 2.80% | |
| NR7 | Range Contraction | 2.80% | |
| Inside Day | Range Contraction | 2.80% | |
| Wide Bands | Range Expansion | 2.80% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Sector: Healthcare
- Industry: Biotechnology
ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company's research operations are in France.
Medicine Medical Specialties Cancer Drug Discovery Autoimmune Diseases Infectious Diseases Infections Antibiotics Bacterial Diseases Healthcare Associated Infections Staphylococcus Aureus Pain
Medicine Medical Specialties Cancer Drug Discovery Autoimmune Diseases Infectious Diseases Infections Antibiotics Bacterial Diseases Healthcare Associated Infections Staphylococcus Aureus Pain
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 32.292 |
| 52 Week Low | 6.91 |
| Average Volume | 1,881,174 |
| 200-Day Moving Average | 10.99 |
| 50-Day Moving Average | 11.73 |
| 20-Day Moving Average | 15.49 |
| 10-Day Moving Average | 19.99 |
| Average True Range | 3.38 |
| ADX | 42.09 |
| +DI | 27.84 |
| -DI | 13.76 |
| Chandelier Exit (Long, 3 ATRs ) | 22.15 |
| Chandelier Exit (Short, 3 ATRs ) | 17.05 |
| Upper Bollinger Band | 28.99 |
| Lower Bollinger Band | 2.00 |
| Percent B (%b) | 0.61 |
| BandWidth | 174.18 |
| MACD Line | 2.59 |
| MACD Signal Line | 2.68 |
| MACD Histogram | -0.0887 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 22.47 | ||||
| Resistance 3 (R3) | 22.48 | 21.12 | 21.79 | ||
| Resistance 2 (R2) | 21.12 | 20.07 | 21.11 | 21.56 | |
| Resistance 1 (R1) | 19.73 | 19.42 | 20.42 | 19.72 | 21.33 |
| Pivot Point | 18.37 | 18.37 | 18.71 | 18.36 | 18.37 |
| Support 1 (S1) | 16.98 | 17.32 | 17.68 | 16.98 | 15.37 |
| Support 2 (S2) | 15.62 | 16.67 | 15.61 | 15.14 | |
| Support 3 (S3) | 14.23 | 15.62 | 14.91 | ||
| Support 4 (S4) | 14.23 |
